Cytoki Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Liquidation

Cytoki General Information

Description

Developer of a clinical-stage biotechnology platform intended to develop IL-22-based therapeutics for metabolic and epithelial injury-related diseases. The company's platform provides engineered long-acting IL-22 analogues, clinical development programs, and translational research activities, enabling patients with conditions such as obesity, type 2 diabetes, and inflammatory bowel disease to receive potential disease-modifying treatments.

Contact Information

Website
www.cytokipharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Vandtårnsvej 77
  • 2860 Søborg
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Vandtårnsvej 77
  • 2860 Søborg
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytoki Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation 21-Sep-2026 Completed Bankruptcy: Liquidation
2. Early Stage VC (Series A) 04-May-2021 Completed Clinical Trials - Phase 2
1. Seed Round 01-Jul-2019 $302K $302K Completed Clinical Trials - Phase 2
To view Cytoki’s complete valuation and funding history, request access »

Cytoki Patents

  • 28

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Cytoki Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4803102-A1 Tissue selective il-22 agonists comprising specific amino acid modifications relative to human il-22 Pending 07-Mar-2025
EP-4389138-A1 Dosage regimen for interleukin-22 derivatives Inactive 22-Dec-2022
EP-4637803-A2 Dosage regimen for interleukin-22 derivatives Inactive 22-Dec-2022
US-20250360186-A1 Dosage regimen for interleukin-22 derivatives Inactive 22-Dec-2022
WO-2024133936-A2 Dosage regimen for interleukin-22 derivatives Inactive 22-Dec-2022 A61K38/20
To view Cytoki’s complete patent history, request access »

Cytoki Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Cytoki FAQs

  • When was Cytoki founded?

    Cytoki was founded in 2019.

  • Where is Cytoki headquartered?

    Cytoki is headquartered in Søborg, Denmark.

  • What is the size of Cytoki?

    Cytoki has 9 total employees.

  • What industry is Cytoki in?

    Cytoki’s primary industry is Drug Discovery.

  • Is Cytoki a private or public company?

    Cytoki is a Private company.

  • What is Cytoki’s current revenue?

    The current revenue for Cytoki is .

  • How much funding has Cytoki raised over time?

    Cytoki has raised $45.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process